(Xantphos)Pd(Ph)Br | 904895-19-8

• 英文名称: (Xantphos)Pd(Ph)Br
• CAS: 904895-19-8
• 化学式: C₄₅H₃₇BrOP₂Pd
• 分子量: 842.06
• InChiKey: URXYCWDFZLXDSK-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  (Xantphos)Pd(Ph)Br 在 potassium fluoride 作用下， 以 乙腈 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  以TMSCF 3为三氟甲基源的芳基Pd（II）配合物羰基化三氟甲基化的化学计量研究

  摘要：

  我们已经进行了一系列的化学计量研究，以确定可行的步骤为一个假设的催化循环的芳族溴化物与TMSCF 3的钯介导的羰基化偶联。我们的工作表明，带有Xantphos或t Bu 3 P作为膦配体的苯甲酰基Pd（II）配合物是由相应的Pd II（Ph）Br配合物从13暴露于化学计量的13 CO中生成的二氧化碳不能进行金属转移和还原消除为三氟苯乙酮。相反，在碱和另外的CO的存在下，这些有机金属配合物容易进行还原性消除为酰氟。试图确定酸性氟化物是否可以代表苯乙酮生产的中间体的尝试是没有意义的。尽管转化效率仍然很低，但只有在硼酸酯存在下，我们才能观察到所需产物的某些形成。最后，我们研究了四种膦连接的Pd II（Ph）CF 3配合物（Xantphos，D t BPF，t Bu 3 P和三苯膦）与一氧化碳的反应性。除了t Bu 3 P连接的配合物，所有其他金属配合物导致三氟乙酰苯的容易形成。我们在三苯基膦的情

  DOI：

  10.1021/acs.organomet.9b00849
• 作为产物：
  描述：

  溴苯 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 以 苯 为溶剂， 反应 4.0h， 以61%的产率得到(Xantphos)Pd(Ph)Br
  参考文献：
  名称：

  以TMSCF 3为三氟甲基源的芳基Pd（II）配合物羰基化三氟甲基化的化学计量研究

  摘要：

  我们已经进行了一系列的化学计量研究，以确定可行的步骤为一个假设的催化循环的芳族溴化物与TMSCF 3的钯介导的羰基化偶联。我们的工作表明，带有Xantphos或t Bu 3 P作为膦配体的苯甲酰基Pd（II）配合物是由相应的Pd II（Ph）Br配合物从13暴露于化学计量的13 CO中生成的二氧化碳不能进行金属转移和还原消除为三氟苯乙酮。相反，在碱和另外的CO的存在下，这些有机金属配合物容易进行还原性消除为酰氟。试图确定酸性氟化物是否可以代表苯乙酮生产的中间体的尝试是没有意义的。尽管转化效率仍然很低，但只有在硼酸酯存在下，我们才能观察到所需产物的某些形成。最后，我们研究了四种膦连接的Pd II（Ph）CF 3配合物（Xantphos，D t BPF，t Bu 3 P和三苯膦）与一氧化碳的反应性。除了t Bu 3 P连接的配合物，所有其他金属配合物导致三氟乙酰苯的容易形成。我们在三苯基膦的情

  DOI：

  10.1021/acs.organomet.9b00849

文献信息

• Efficient ¹¹C-Carbonylation of Isolated Aryl Palladium Complexes for PET: Application to Challenging Radiopharmaceutical Synthesis
  作者：Thomas L. Andersen、Stig D. Friis、Hélène Audrain、Patrik Nordeman、Gunnar Antoni、Troels Skrydstrup

  DOI：10.1021/ja511441u

  日期：2015.2.4

  We describe the successful implementation of palladium-aryl oxidative addition complexes as stoichiometric reagents in carbonylation reactions with (CO)-C-11 to produce structurally challenging, pharmaceutically relevant compounds. This method enables the first C-11-carbonyl labeling of an approved PET tracer, [C-11]raclopride, for the dopamine D2/D3 receptor by carbonylation with excellent radiochemical purity and yield. Two other molecules, [C-11]olaparib and [C-11]JNJ 31020028, were efficiently labeled in this manner. The technique distinguishes itself from existing methods by the markedly improved purity profiles of the tracer molecules produced and provides access to complex structures in synthetically useful yields, hereby offering a viable alternative to other C-11-labeling strategies.
• Organometallic Chemistry of Amidate Complexes. Accelerating Effect of Bidentate Ligands on the Reductive Elimination of <i>N</i>-Aryl Amidates from Palladium(II)
  作者：Ken-ichi Fujita、Makoto Yamashita、Florian Puschmann、Miguel Martinez Alvarez-Falcon、Christopher D. Incarvito、John F. Hartwig

  DOI：10.1021/ja062333n

  日期：2006.7.19

  We report a series of arylpalladium complexes of acetamidate, sulfonamidate, and deprotonated oxazolidinone ligands that undergo reductive elimination with rates and yields that depend on the binding mode of the ancillary and amidate ligands. Complexes of the acetamidate ligands containing the bidentate phosphines DPPF and Xantphos as ancillary ligands undergo reductive elimination. The rate and yield were higher from the complex ligated by Xantphos, which contains a larger bite angle. In contrast, the analogous amidate complex containing a single sterically hindered monodentate ligand and a kappa2-bound amidate ligand does not undergo reductive elimination. This trend of faster reductive elimination from complexes containing bidentate ancillary ligands than from a complex with a single monodentate ancillary ligand is unusual and is consistent with an effect of the denticity of the ancillary ligand on the binding mode of the amidate. Complexes of sulfonamidate ligands underwent reductive elimination faster than complexes of acetamidates, and reductive elimination occurred from complexes containing both bidentate and monodentate ancillary ligands. Like reductive elimination from the acetamidate complexes, reductive eliminations from the sulfonamidate complexes were faster when the complexes possessed bidentate Xantphos and kappa1-sulfonamidate ligands.